Thermo Fisher Scientific, Inc., Takeda Pharmaceutical Co., Ltd., Merck KGaA are Dominating the Global Stem Cell Manufacturing Market in 2020

Global Stem Cell Manufacturing Market is expected to grow with the CAGR of 10.1% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-stem-cell-manufacturing-market

Global stem cell manufacturing market is a highly consolidated market. The market has witnessed increased strategic developments owing to favourable market scenario.    

The major players dealing in global stem cell manufacturing market are introducing strong range of stem cell based products along with launching new products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance,

  • In January 2021, Thermo Fisher Scientific Inc. launched new medium for the development of human T lymphocytes for allogenic cell therapy. The media solution targets the metabolism of healthy donor cells and making it ideal for use in the production of allogenic cell therapies. This will help the company for research use or manufacturing of cell, gene or tissue based products. However, it is not intended for direct administration to humans.

Thermo Fisher Scientific Inc. is the dominating player in global stem cell manufacturing market. The other key players existing in the market includes are Merck KGaA, BD, Organogenesis Inc., Vericel Corporation, ANTEROGEN. CO., LTD., VistaGen Therapeutics, Inc., FUJIFILM Cellular Dynamics, Inc., American CryoSystem Corporation, PromoCell GmbH, Sartorius AG, ViaCyte, Inc., STEM CELL Technologies, Inc., Takeda Pharmaceutical Company Limited, DAIICHI SANKYO COMPANY, LIMITED, Bio-Techne, REPROCELL Inc., Catalent, Inc, Mesoblast Ltd, Astellas Pharma Inc. among others.

Stem Cell Manufacturing MarketThermo Fisher Scientific Inc.

Thermo Fisher Scientific Inc. was established in 1960, and headquartered in Massachusetts, U.S. The company focuses on manufacturing scientific instruments, consumables, and chemicals. The company’s business segments include Life Science Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Services in which the market focused segment is Life Science Solutions. The company also provides various product categories including Life Sciences, Industrial and Applied Science, Clinical Diagnostics, Lab Solutions, Digital Solutions in which the market focus products lie under Life Sciences category.

For instance,

  • In In February 2017, Thermo Fisher Scientific Inc. announced the launch of Gibo Stem Flex Medium. It is designed to respond to stem cell research challenge and performs in modern applications like gene editing, single cell passaging, reprogramming among others. This has helped the company to improve the medium which tests better than standard media on metrics.

The company has wide presence in Americas, Europe, Middle East and Africa, Asia-Pacific. The company also has subsidiaries such as Patheon (U.S.), Dionex (U.S.), Cole Palmer (U.S.), Affymertrix (U.S.), Applied Biosystems (U.S.) among others.  

Takeda Pharmaceutical Co., Ltd.

Takeda Pharmaceutical Co., Ltd.  was incorporated in 1781 and headquartered in Japan. The company engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It has following business segments including Gastroenterology, Rare Diseases, Rare Hematology, Hereditary Angioedema, PDT Immunology, Oncology, Neuroscience and Others in which Oncology & Gastroenterology are the market focused segment. The company also provides various product categories including Oncology, Rare Diseases, Neuroscience, Gastroenterology, Plasma-Derived Therapies, and Vaccines in which the market focus products lie under Oncology & Gastroenterology.

For instance,

  • In February 2021, Takeda Pharmaceutical Company Limited announced the expansion of stem cell therapy production in Ireland. This expansion will help the company to acquire the market in coming years.

The company has wide presence across Americas, Europe, Middle East and Africa and Asia-Pacific. The company also has various subsidiary companies such Takeda Pharmaceutical U.S.A. Inc. (U.S.), Takeda France SAS (France), Takeda Canada, Inc. (Canada), Takeda UK Limited (U.K.), TiGenix (Belgium) among others.

Merck KGaA

Merck KGaA was founded in 1668, headquartered in Darmstadt, Germany. The company  is a science and technology company, which engages in the manufacture of pharmaceutical and chemical products. It has following business segments Healthcare, Life Science, Performance Materials Corporate and others in which Life Science is the market focused segment. The company also provides various product categories including Healthcare, Life Science and Electronics in which the market focus products lie under Life Science.

For instance,

  • In May 2021, Merck KGaA, announced the extension of its ongoing collaboration with BioMed X, Heidelberg, Germany. Under the new agreement, Merck will start up to six additional research projects at the BioMed X Institute, building on ongoing research projects in the fields of oncology (DNA damage response and RNA splicing) and autoimmunity (intestinal epithelial barrier in autoimmune diseases). As a result of this successful collaboration, multiple innovative discovery projects in new research areas have been started at Merck. 

The company has wide presence across Europe, Americas, Asia-Pacific, Middle East and Africa. The company has various subsidiary companies such as Sigma-Aldrich (U.S.), MilliporeSigma (U.S.), Merck S.A. (France), Merck Ltd. (Japan), Asceneuron SA (Switzerland), among others.